StockData
Oncotelic Therapeutics, Inc. logo

Oncotelic Therapeutics, Inc. (OTLC) stock

OTLCOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.02+0.00 (+11.45%)

Close on Oct 19, 2026Market cap $8.66MP/E 0.0Yield –

Oncotelic Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Oncotelic Therapeutics's revenue for the twelve months ending Dec 31, 2023 was $70.00K. For fiscal 2023 it was $70.00K, down 96.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2023Dec 31, 2023$70.00K-96.0%
FY2020Dec 31, 2020$1.74M+1732.5%
FY2013Dec 31, 2013$95.00K-39.1%
FY2012Dec 31, 2012$156.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$250.00K–
Q4 FY2023Dec 31, 2023$0-100.0%
Q3 FY2023Sep 30, 2023$70.00K-79.5%
Q4 FY2020Dec 31, 2020$0–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$1.40M–
Q1 FY2020Mar 31, 2020$340.86K–

More Oncotelic Therapeutics figures

See a number that looks wrong?